Galmed Pharmaceuticals (NASDAQ: GLMD) and BIOVERATIV INC (NASDAQ:BIVV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.


This table compares Galmed Pharmaceuticals and BIOVERATIV INC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galmed Pharmaceuticals -1,443.98% -141.13% -99.09%

Insider and Institutional Ownership

8.3% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.9% of BIOVERATIV INC shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Galmed Pharmaceuticals and BIOVERATIV INC’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Galmed Pharmaceuticals $1.00 million 113.51 -$14.30 million ($1.22) -7.61
BIOVERATIV INC $1.03 billion 5.95 $441.10 million N/A N/A

BIOVERATIV INC has higher revenue and earnings than Galmed Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Galmed Pharmaceuticals and BIOVERATIV INC, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals 0 0 2 0 3.00
BIOVERATIV INC 1 8 6 1 2.44

Galmed Pharmaceuticals presently has a consensus price target of $16.00, indicating a potential upside of 72.23%. BIOVERATIV INC has a consensus price target of $60.36, indicating a potential upside of 6.62%. Given Galmed Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Galmed Pharmaceuticals is more favorable than BIOVERATIV INC.


BIOVERATIV INC beats Galmed Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.


Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.